Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amylyx Pharmaceuticals Inc (AMLX)

Amylyx Pharmaceuticals Inc (AMLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Amylyx Pharmaceuticals Inc 43 Thorndike St. Cambridge MA 02141 USA

www.amylyx.com Employees: 123 P: 617-682-0917

Sector:

Medical

Description:

Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass.

Key Statistics

Overview:

Market Capitalization, $K 1,817,521
Enterprise Value, $K 1,740,131
Shares Outstanding, K 109,820
Float, K 96,312
% Float 87.70%
Short Interest, K 13,642
Short Float 12.42%
Days to Cover 7.51
Short Volume Ratio 0.49
% of Insider Shareholders 12.30%
% of Institutional Shareholders 95.84%

Financials:

Annual Sales, $ 87,370 K
Annual Net Income, $ -301,740 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -34,390 K
EBIT, $ -157,340 K
EBITDA, $ -166,290 K

Growth:

1-Year Return 388.99%
3-Year Return -59.57%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.37 on 11/06/25
Next Earnings Date 03/03/26
Earnings Per Share ttm -1.80
EPS Growth vs. Prev Qtr 19.57%
EPS Growth vs. Prev Year 30.19%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Next Ex-Dividends Date 03/28/18
Dividend Payable Date 04/02/18
Dividend Payout Ratio 0.00%

AMLX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -68.95%
Return-on-Assets % -61.52%
Profit Margin % -345.36%
Debt/Equity 0.00
Price/Sales -2,753.82
Price/Cash Flow N/A
Price/Book 4.73
Book Value/Share 3.02
Interest Coverage -1.20
60-Month Beta -0.31
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar